On October 30, 2025, the Company's Board of Directors authorized a new $750 million share repurchase program, which begins on January 1, 2026, and expires on December 31, 2028. This program is ...
Q3 2025 Earnings Call November 6, 2025 8:30 AM ESTCompany ParticipantsKate Africk - Head of Investor RelationsLawrence Fey - ...
The deceleration in CKD prevalence growth after 2012, along with the declining incidence trends may reflect the impact of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback